166 related articles for article (PubMed ID: 38748286)
81. Evaluation of diagnostic performance of whole-body simultaneous PET/MRI in pediatric lymphoma.
Ponisio MR; McConathy J; Laforest R; Khanna G
Pediatr Radiol; 2016 Aug; 46(9):1258-68. PubMed ID: 27003132
[TBL] [Abstract][Full Text] [Related]
82. (11)C-acetate as a new biomarker for PET/CT in patients with multiple myeloma: initial staging and postinduction response assessment.
Lin C; Ho CL; Ng SH; Wang PN; Huang Y; Lin YC; Tang TC; Tsai SF; Rahmouni A; Yen TC
Eur J Nucl Med Mol Imaging; 2014 Jan; 41(1):41-9. PubMed ID: 24129710
[TBL] [Abstract][Full Text] [Related]
83. Repeatability of Quantitative Whole-Body 18F-FDG PET/CT Uptake Measures as Function of Uptake Interval and Lesion Selection in Non-Small Cell Lung Cancer Patients.
Kramer GM; Frings V; Hoetjes N; Hoekstra OS; Smit EF; de Langen AJ; Boellaard R
J Nucl Med; 2016 Sep; 57(9):1343-9. PubMed ID: 27103020
[TBL] [Abstract][Full Text] [Related]
84. Clinicopathological characteristics of primary central nervous system lymphoma with low 18F-fludeoxyglucose uptake on brain positron emission tomography.
Kim HO; Kim JS; Kim SO; Chae SY; Oh SJ; Seo M; Lee SH; Oh JS; Ryu JS; Huh JR; Kim JH
Medicine (Baltimore); 2020 May; 99(20):e20140. PubMed ID: 32443328
[TBL] [Abstract][Full Text] [Related]
85. Early dynamic 18F-FDG PET to detect hyperperfusion in hepatocellular carcinoma liver lesions.
Schierz JH; Opfermann T; Steenbeck J; Lopatta E; Settmacher U; Stallmach A; Marlowe RJ; Freesmeyer M
J Nucl Med; 2013 Jun; 54(6):848-54. PubMed ID: 23528383
[TBL] [Abstract][Full Text] [Related]
86. Multiple metabolic parameters and visual assessment of
Ren Y; Liu J; Wang L; Luo Y; Ding X; Shi A; Liu J
Abdom Radiol (NY); 2020 Nov; 45(11):3569-3580. PubMed ID: 32274551
[TBL] [Abstract][Full Text] [Related]
87. Whole body magnetic resonance with diffusion weighted sequence with body signal suppression compared to (18)F-FDG PET/CT in newly diagnosed lymphoma.
Ferrari C; Minoia C; Asabella AN; Nicoletti A; Altini C; Antonica F; Ficco M; Guarini A; Maggialetti N; Rubini G
Hell J Nucl Med; 2014; 17 Suppl 1():40-9. PubMed ID: 24392468
[TBL] [Abstract][Full Text] [Related]
88. Clinical importance of [
Skoura E; Datseris IE; Exarhos D; Chatziioannou S; Oikonomopoulos G; Samartzis A; Giannopoulou C; Syrigos KN
Oncol Lett; 2013 May; 5(5):1687-1693. PubMed ID: 23761835
[TBL] [Abstract][Full Text] [Related]
89. Comparison of trans-1-amino-3-[18F]fluorocyclobutanecarboxylic acid (anti-[18F]FACBC) accumulation in lymph node prostate cancer metastasis and lymphadenitis in rats.
Kanagawa M; Doi Y; Oka S; Kobayashi R; Nakata N; Toyama M; Shirakami Y
Nucl Med Biol; 2014 Aug; 41(7):545-51. PubMed ID: 24816330
[TBL] [Abstract][Full Text] [Related]
90.
Diwanji D; Onishi N; Hathi DK; Lawhn-Heath C; Kornak J; Li W; Guo R; Molina-Vega J; Seo Y; Flavell RR; Heditsian D; Brain S; Esserman LJ; Joe BN; Hylton NM; Jones EF; Ray KM
Radiol Imaging Cancer; 2024 Mar; 6(2):e230082. PubMed ID: 38551406
[TBL] [Abstract][Full Text] [Related]
91.
Michaud L; Beattie BJ; Akhurst T; Dunphy M; Zanzonico P; Finn R; Mauguen A; Schöder H; Weber WA; Lassman AB; Blasberg R
Eur J Nucl Med Mol Imaging; 2020 Jun; 47(6):1353-1367. PubMed ID: 31418054
[TBL] [Abstract][Full Text] [Related]
92. Preoperative
Aymard S; Rust E; Kaseb A; Liu D; Hubele F; Romain B; Averous G; Brigand C; Imperiale A
Cancers (Basel); 2024 Jan; 16(1):. PubMed ID: 38201660
[TBL] [Abstract][Full Text] [Related]
93. Comparative evaluation of
Norikane T; Yamamoto Y; Maeda Y; Noma T; Dobashi H; Nishiyama Y
EJNMMI Res; 2017 Aug; 7(1):69. PubMed ID: 28853043
[TBL] [Abstract][Full Text] [Related]
94. Early prediction of response to chemotherapy in metastatic breast cancer using sequential 18F-FDG PET.
Dose Schwarz J; Bader M; Jenicke L; Hemminger G; Jänicke F; Avril N
J Nucl Med; 2005 Jul; 46(7):1144-50. PubMed ID: 16000283
[TBL] [Abstract][Full Text] [Related]
95. Treatment response evaluation with
Sachpekidis C; Hillengass J; Goldschmidt H; Wagner B; Haberkorn U; Kopka K; Dimitrakopoulou-Strauss A
Eur J Nucl Med Mol Imaging; 2017 Jan; 44(1):50-62. PubMed ID: 27573638
[TBL] [Abstract][Full Text] [Related]
96. Whole-body MRI with diffusion-weighted imaging: a valuable alternative to contrast-enhanced CT for initial staging of aggressive lymphoma.
Balbo-Mussetto A; Cirillo S; Bruna R; Gueli A; Saviolo C; Petracchini M; Fornari A; Lario CV; Gottardi D; De Crescenzo A; Tarella C
Clin Radiol; 2016 Mar; 71(3):271-9. PubMed ID: 26749081
[TBL] [Abstract][Full Text] [Related]
97.
Albano D; Tomasini D; Bonù M; Giubbini R; Bertagna F
Ann Nucl Med; 2020 Feb; 34(2):81-86. PubMed ID: 31773466
[No Abstract] [Full Text] [Related]
98. Assessment of Central Nervous System Lymphoma Based on CXCR4 Expression In Vivo Using 68Ga-Pentixafor PET/MRI.
Starzer AM; Berghoff AS; Traub-Weidinger T; Haug AR; Widhalm G; Hacker M; Rausch I; Preusser M; Mayerhoefer ME
Clin Nucl Med; 2021 Jan; 46(1):16-20. PubMed ID: 33208624
[TBL] [Abstract][Full Text] [Related]
99. Relationship between pretreatment FDG-PET and diffusion-weighted MRI biomarkers in diffuse large B-cell lymphoma.
de Jong A; Kwee TC; de Klerk JM; Adam JA; de Keizer B; Fijnheer R; Kersten MJ; Ludwig I; Jauw YW; Zijlstra JM; Pieters-Van den Bos IC; Stoker J; Hoekstra OS; Nievelstein RA
Am J Nucl Med Mol Imaging; 2014; 4(3):231-8. PubMed ID: 24795837
[TBL] [Abstract][Full Text] [Related]
100. Comparison of [
Chen H; Pang Y; Li J; Kang F; Xu W; Meng T; Shang Q; Zhao J; Guan Y; Wu H; Xie F; Wang J; Sun L
Eur Radiol; 2023 Feb; 33(2):1329-1341. PubMed ID: 35976396
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]